<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005066</url>
  </required_header>
  <id_info>
    <org_study_id>2018-013-00CH2</org_study_id>
    <nct_id>NCT04005066</nct_id>
  </id_info>
  <brief_title>Study of Elunate® (Fruquintinib) in Chinese Patients With Advanced CRC</brief_title>
  <official_title>A Prospective, Double-cohort, Multi-center, Phase IV Study to Further Characterize</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase IV study to characterize safety of Elunate® (Fruquintinib) in Chinese patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, double-cohort, phase IV study, to evaluate safety of
      Elunate® (Fruquintinib) in Chinese patients. There're 3 visits, including signing the ICF, 1
      month after signing the ICF, 6 months after signing the ICF or 30 days after the last day of
      treatment. Patients who are using Elunate® or plan to use Elunate® within 1 week could be
      enrolled to this study. There're 2 cohorts for this study as below:

      Cohort 1: metastatic colorectal cancer patients who are in accordance with Elunate® package
      insert, the sample size is 2000; Cohort 2: other patients suitable for treatment with
      Elunate® according to investigator's judgement, the sample size is 1000.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohort 1: metastatic colorectal cancer patients who are accordance with Elunate® package insert, the sample size is 2000; Cohort 2: other patients suitable for according to investigator's judgement, the sample size is 1000.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>from the first administration of fruquintinib up to 6 months</time_frame>
    <description>% of patients with AEs according to CTCAE 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of ADRs</measure>
    <time_frame>from the first administration of fruquintinib up to 6 months</time_frame>
    <description>% of patients with ADRs according to CTCAE 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of SAEs</measure>
    <time_frame>from the first administration of fruquintinib up to 6 months</time_frame>
    <description>% of patients with SAEs according to CTC AE 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AESI</measure>
    <time_frame>from the first administration of fruquintinib up to 6 months</time_frame>
    <description>% of patients with AESI according to CTC AE 4.03</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>metastatic colorectal cancer patients who are accordance with Elunate® package insert</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>other patients suitable for according to investigator's judgement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elunate®</intervention_name>
    <description>Fruquintinib treatment: 4mg in the Cycle 1,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.5mg ,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Fruquintinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Basic inclusion criteria for both cohort 1&amp;cohort 2:

               -  Currently using Elunate® or will use Elunate® within a week;

               -  Provision of informed consent by the patient.

        Cohort 1: Besides 2 criteria above, there're 3 more inclusion criteria for Cohort 1:

          -  Diagnosed metastatic colorectal cancer;

          -  ECOG PS ≤2 (0-2)；

          -  Patients are suitable to use Elunate® according to investigator's judgement. Cohort 2:
             Patients only meet 2 basic inclusion criteria and suitable to use Elunate® according
             to investigator's judgement could be enrolled in cohort 2.

        Exclusion Criteria:

          -  Exclusion criteria for both cohort 1&amp; cohort 2:

               -  Unsuitable for the experiment according to investigator's judgement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xijie Zhang</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison Medipharma Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xijie Zhang</last_name>
    <phone>86-020-37874391</phone>
    <email>xijiez@hmplglobal.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiao Yan</last_name>
    <phone>86-021-20673225</phone>
    <email>qiaoy@hmplglobal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Dongfang Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li, PH.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

